BioMarin Pharmaceutical Inc. (BMRN)

AQR Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 90.7% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 5,580,573 shares of the biotechnology company's stock after buying an additional 2,654,768 shares during the period. AQR Capital Management

BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) and Contineum Therapeutics (NASDAQ: CTNM - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Risk and Volatility BioMarin Pharmaceutical has a beta

BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.

Envestnet Asset Management Inc. lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 15.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,753 shares of the biotechnology company's stock after purchasing an additional

Alberta Investment Management Corp acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,200 shares of the biotechnology company's stock, valued at approximately $4,024,000. Other large investors have also

Acadian Asset Management LLC grew its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 285.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,600 shares of the biotechnology company's stock after buying an additional 68,589 shares during

SAN RAFAEL, Calif. , Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.

D.A. Davidson and CO. grew its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 4.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,119 shares of the biotechnology company's stock after buying an additional 331 shares during the quarter. D.A. Davidson

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone FDA PDUFA target action date of Feb. 28, 2026 SAN RAFAEL, Calif. , Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ ® (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) to expand treatment to include adolescents aged 12-17 with phenylketonuria (PKU).

Asset Management One Co. Ltd. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,963 shares of the biotechnology company's stock after buying an additional 7,084

The biotech published its latest set of quarterly results. It posted a surprise net profit for the period.

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

BioMarin Pharmaceuticals shares have fallen to decade lows, reflecting investor concerns despite profitable growth and a strong net cash position. Its results showed double-digit revenue growth, but recent quarters revealed slowing sales momentum, especially for key drugs like Voxzogo and Roctavian. Competition and product setbacks cast doubt on achieving 2027 growth targets, even as the company maintains a sub-3x sales multiple and robust cash reserves.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2025 Earnings Call October 27, 2025 4:30 PM EDT Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Julian Pino Christopher Raymond - Raymond James & Associates, Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Presentation Operator Hello, and welcome to the BioMarin Pharmaceutical Third Quarter 2025 Conference Call. [Operator Instructions].

BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading.

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.